Our take
SS Innovations is growing quickly. Its SSi Mantra had 224 systems installed across twelve countries and 12,272 surgeries performed by June 30, 2026, including cardiac, pediatric, and long-distance telesurgery cases.1 For hospitals in markets where the leading systems are too expensive, it is a credible alternative.
For US buyers it is not yet an option. The company answered an FDA request for more information in October 2026 and expects the agency to finish reviewing its 510(k) submission in the first quarter of 2027, for an initial gallbladder removal indication.2
Scores by criterion
Each criterion is defined on our methodology page.
Who uses SS Innovations and what it's for
SS Innovations has an established presence in India and is expanding abroad.4 The first SSi Mantra went to the Rajiv Gandhi Cancer Institute and Research Centre in New Delhi in 2022.3 By mid-2026 its installed base covered twelve countries, and its cumulative surgeries included 175 telesurgeries, 637 cardiac procedures, and 222 pediatric surgeries.1
Buyers compare the SSi Mantra with Intuitive Surgical's da Vinci, the market leader, and with other new multi-arm systems. The company's case rests on price and on breadth, including cardiac surgery.3,4
One system for general and cardiac surgery
The SSi Mantra is a surgical robot that SS Innovations describes as cost-efficient and suited to a wide range of procedures, including cardiac surgery.4 It is a modular system with 3 to 5 robotic arms, an open surgeon console, and a 3D 4K monitor.2 Installations rose to 30 in the second quarter of 2026, up from 23 a year earlier, and quarterly surgeries rose to 2,528 from 1,042.1
Long-distance telesurgery
On July 29, 2026, surgeons led by founder Sudhir Srivastava used the SSi Mantra to perform a sleeve gastrectomy remotely from Bucaramanga, Colombia, on a patient in Indore, India, across more than 13,600 miles of fiber network. The company says that broke its own earlier distance record.1
As of September 28, 2026 the SSi Mantra had supported 195 robotic telesurgeries, and SS Innovations reported a 45% increase in its installed base to 244 systems across 12 countries, with 14,503 cumulative procedures and about 1,500 physicians trained.6
Pricing far below the market leader
SS Innovations does not publish a list price. Business Standard reported in 2022 that the SSi Mantra cost around Rs 4.5 crore against Rs 15 crore for a da Vinci, less than a third of the price.3 That is a useful reference point, but it is four years old and in rupees, so we treat it as a partial price disclosure.
A newer reference comes from the company's own results: first-half 2026 system sales of $21.9 million across 56 installations, or about $391,700 per system (our calculation). Our surgical robot cost report sets that beside da Vinci, Hugo, and Versius prices.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where SS Innovations wins or loses |
|---|---|---|---|---|
| SS Innovations | SSi Mantra modular surgical robot4 | Less than a third of a da Vinci's price in a 2022 report3 | 224 systems in twelve countries by June 30, 2026; not yet FDA cleared1,2 | Lower price and telesurgery; no US clearance yet |
| Intuitive (da Vinci) | da Vinci multi-port and single-port surgical systems7 | Sales plus leases, many with usage-based payments7 | About 12,094 systems installed at September 30, 20267 | Intuitive wins on installed base, training, and US clearances. SSi wins on price in markets where da Vinci is out of reach. |
| Medtronic | Hugo robotic-assisted surgery system8 | Not published8 | FDA cleared in December 2025 for urologic procedures8 | Medtronic wins on a US clearance and a global sales force. SSi wins on cost and cardiac cases. |
| CMR Surgical (Versius) | Versius Plus modular surgical robot9 | Not published9 | 45,000 cases worldwide; FDA 510(k) for gallbladder removal9 | CMR wins on a US clearance for the same first indication SSi is seeking. SSi wins on price. |
| Distalmotion (DEXTER) | DEXTER soft-tissue surgical robot with a small, mobile footprint11 | Not published11 | Almost 3,000 patients treated; three US clearances11 | Distalmotion wins on US clearances for outpatient procedures. SSi wins on price and cardiac cases. |
| Moon Surgical | Maestro bedside assistant with ScoPilot AI camera control15 | Not published13 | FDA cleared in 2024; dataset of more than 3,000 procedures12,15 | SS Innovations wins on a low-cost telerobot. Moon wins on fitting existing laparoscopic tools and workflows. |
Limits
Not cleared for sale in the United States. FDA review of the 510(k) is expected in the first quarter of 2027.2
Losses continue. The company reported a net loss of $2.7 million in the second quarter of 2026, and second-quarter gross margin fell to 50.9% from 59.1% a year earlier, although first-half gross margin rose to 49.6% from 46.3%. It had $13.6 million in cash and no long-term debt on June 30, 2026.1
The only public price reference is a 2022 press report.3
What customers say
Where it helps
We found no independent surgeon or hospital reviews to quote. The case for the system in public material rests on volume: 12,272 surgeries across 224 installations, and growth in procedures per system.1
Where it falls short
The drawbacks in public material are the lack of US clearance, a lower gross margin in the second quarter of 2026, and continued net losses.2,1
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: SS Innovations financial results and FDA update, and Business Standard reporting.
Leadership

Sudhir Srivastava
Founder, chairman, and chief executive officerDr. Srivastava is a cardiac surgeon who was working in Texas, returned to India in 2011, and started SS Innovations in 2014.3,5

Vishwa Srivastava
Chief executive officer, Asia PacificDr. Vishwa Srivastava sits on the boards of both the US parent and the Indian operating company and leads the Asia Pacific business.5

Sources
- SS Innovations, Second quarter 2026 financial results, August 13, 2026, accessed November 9, 2026
- SS Innovations, Response to FDA request for additional information on the SSi Mantra 510(k), October 13, 2026, accessed November 9, 2026
- Business Standard, The SSI Mantra: India’s own surgical robot boasts cheaper price tag, September 15, 2022, accessed November 9, 2026
- SS Innovations, Investor overview, accessed November 9, 2026
- SS Innovations, Leadership, accessed November 9, 2026
- NetworkNewsWire, SS Innovations advances telerobotic surgery with 195 remote procedures, November 5, 2026, accessed November 9, 2026
- Intuitive, Form 10-Q for the quarter ended September 30, 2026, SEC, accessed November 9, 2026
- Medtronic, FDA clearance of Hugo robotic-assisted surgery system for urologic surgical procedures, December 3, 2025, accessed November 9, 2026
- CMR Surgical, Homepage, accessed November 9, 2026
- Medtronic, Sphere-9 and PulseSelect registry results, October 22, 2026, accessed November 1, 2026
- Distalmotion, Distalmotion raises $150 million, November 18, 2025, accessed November 1, 2026
- Sofinnova Partners, Moon Surgical receives second FDA clearance, covering its commercial Maestro surgical robotics system, June 4, 2024, accessed November 3, 2026
- Moon Surgical, Homepage, accessed November 3, 2026
- PR Newswire, Moon Surgical and KARL STORZ announce strategic commercial collaboration, July 22, 2026, accessed November 3, 2026
- PR Newswire, Moon Surgical expands Maestro platform into a multi-model physical AI platform with software version 2.7, June 9, 2026, accessed November 3, 2026
